Harshraj Leuva, Ryon P. Graf, Gerald Li, Jeffrey S. Ross, Mengxi Zhou, Shekhar Bhatta, Neha Vapiwala, Abigail Pepin, Kerry Roe Schaffer, Antonio Tito Fojo. "TP53 mutations (TP53mut) as a predictive biomarker for lutetium-177-PSMA (Lu-PSMA) vs. docetaxel benefit in post-androgen receptor pathway inhibitors (ARPI) metastatic castration-resistant prostate cancer (mCRPC).." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.7_suppl.28